Is Incyte Stock Outperforming the Dow?

Valued at a market cap of $13.3 billion, Incyte Corporation (INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics for hematology/oncology and inflammation and autoimmunity areas. The Wilmington, Delaware-based company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.

Companies valued at over $10 billion are typically classified as “large-cap stocks,” Incyte fits the label perfectly with its market cap exceeding this threshold. The company’s lead drug, Jakafi (ruxolitinib), is approved in the United States for the treatment of patients with polycythemia vera ('PV') who have had an inadequate response to or are intolerant to hydroxyurea and is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF).